NCT01854710View on ClinicalTrials.gov

ADASUVE 2-dose Thorough QT/QTc Study

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Healthy Volunteers
Interventions
DRUG

ADASUVE 10 mg 2 doses 2 hours apart

Inhaled loxapine 10 mg 2 doses 2 hours apart

DRUG

Inhaled Placebo

Staccato placebo via inhalation x 2 at 2 hours apart

DRUG

Oral moxifloxacin 400 mg

Oral moxifloxacin 400 mg single dose

DRUG

Oral placebo

Oral capsule identical in appearance to moxifloxacin

Trial Locations (1)

Unknown

PRA International, Zuidlaren

Sponsors
All Listed Sponsors
lead

Alexza Pharmaceuticals, Inc.

INDUSTRY